E/NL. 1957/133 - 134
5 February 1958
ENGLISH
Original: POLISH

UNITED NATIONS

LAWS AND REGULATIONS

PROMULGATED TO GIVE EFFECT TO THE PROVISIONS OF THE CONVENTION OF 13 JULY 1931 FOR LIMITING THE MANUFACTURE AND REGULATING THE DISTRIBUTION OF NARCOTIC DRUGS, AS AMENDED BY THE PROTOCOL OF 11 DECEMBER 1946

POLAND

Communicated by the Government of Poland

NOTE BY THE SECRETARY-GENERAL -- In accordance with Article 21 of the Convention of 13 July 1931 for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs, as amended by the Protocol of 11 December 1946, the Secretary-General has the honour to communicate the following legislative texts.

E/NL.1957/133

No. 195

ORDER OF THE MINISTER OF HEALTH

of 13 September 1956

concerning the classification of certain substances as narcotic drugs

Having regard to article 5, paragraph 2, of the Act of 8 January 1951 on Pharmaceutical Products, Narcotic Drugs and Medical Appliances[1] (Dziennik Ustaw No. 1, item 4), it is hereby ordered as follows:

1. The undermentioned substances are hereby classified as narcotic drugs:

(1) Methylmorphine (codeine)
(2) Ethylmorphine (the hydrochloride of which is Dionine)
(3) Other ethers of morphine
(4) Dihydrocodeine (the tartrate of which is Paracodine)
(5) Acetyldihydrocodeine
(6) 4-(3-hydroxyphenyl)-1-methyl-4-piperidyl ethyl ketone [Ketobemidone][2] (the hydrochloride of which is Cliradon)
(7) 1-methyl-4-(3-hydroxyphenyl)-piperidine-4-carboxylic acid ethyl ester (Bemidone) [Hydroxypethidine]
(8) α-1,3-dimethyl-4-phenyl-4-propionoxypiperidine (Alphaprodine)
(9) β-1,3-dimethyl-4-phenyl-4-propionoxypiperidine (Betaprodine)
(10) 6-dimethylamino-4,4-diphenyl-5-methyl-3-hexanone (Isomethadone)
(11) 6-dimethylamino-4,4-diphenyl-heptanone-3 (Methadone)
(12) α-6-dimethylamino-4,4-diphenyl-3-heptanol [Alphamethadol]
(13) 6-dimethylamino-4,4-diphenyl-3-acetoxyheptane (Acetylmethadol)
(14) α-6-dimethylamino-4,4-diphenyl-3-acetoxyheptane (Alphacetylmethadol)
(15) β-6-dimethylamino-4,4-diphenyl-3-acetoxyheptane (Betacetylmethadol)
(16) β-1-methyl-3-ethyl-4-phenyl-4-propionoxypiperidine (Meprodine) [Betameprodine]
(17) DL-3-hydroxy-N-methylmorphinan (Racemorphan)
(18) L-3-hydroxy-N-methylmorphinan (Levorphanol)
(19) DL-3-methoxy-N-methylmorphinan (Racemethorphan)

1/ Note by the Secretariat: E/NL 1953/92.

2/ Note by the Secretariat: The words in square brackets have been inserted by the Secretariat. Proposed or recommended international non-proprietary names of drugs are underlined.

(20) L-3-methoxy-N-methylmorphinan (Levomethorphan)
(21) 3-Dimethylamino-1,1-di-(2'-thienyl)-1-butene /Dimethylthiambutene/
(22) 3-ethylmethylamino-1,1-di-(2'-thienyl)-1-butene /Ethylmethylthiambutene/
(23) Salts of the products enumerated in (1) to (22) and mixtures containing the said products or their salts.

2. This Order shall enter into force on the day of its publication.

for B. Bednarski
Minister of Health

E/NL.1957/134

No. 196

ORDER OF THE MINISTERS OF HEALTH AND FOREIGN TRADE

of 13 September 1956

concerning Narcotic Drugs

Having regard to article 18, paragraph 3, of the Act of 8 January 1951 on Pharmaceutical Products, Narcotic Drugs and Medical Appliances (Dziennik Ustaw No. 1 item 4) and article 13, paragraph 3 of the Customs Code of 27 October 1933 (Dziennik Ustaw 1933, No. 84, item 610; 1945, No. 12, item 64; 1946, No. 34, item 209 and 1952, No. 10, item 53) it is hereby ordered as follows:

CHAPTER I

Introductory provisions

1. In conformity with the international conventions in force, narcotic drugs shall be divided, according to their effect and use, into four groups: I A, I B, I C and II, as shown in annex 1 to this Order.

2.(1) The manufacture, processing, placing on the market, possession and use of narcotic drugs in groups I A, I B and II shall not be lawful except as authorized in conformity with the provisions of this Order.

(2) The manufacture, processing and placing on sale of narcotic drugs in group I C shall be prohibited.

(3) Narcotic drugs in group I C may only be possessed and used by institutions of higher education, scientific institutes and other scientific establishments and solely for scientific purposes; such drugs may only be obtained from a wholesaler designated by the Minister of Health.

3. This Order shall not apply to ethyl ether.

4.(1) A consignment containing any narcotic drugs in groups I A, I B, or I C may not contain any other product or object in the same package.

(2) The consignee of any consignment of narcotic drugs shall within seven days from the date of receipt thereof transmit to the sender a written acknowledgment with an accurate statement of the nature and quantity of the products received.

CHAPTER II

Importation, exportation and transit of narcotic drugs

5.(1) Any person or establishment wishing to import or export narcotic drugs must obtain, in addition to the licence required under the provisions governing the import and export of goods, an import certificate in the form shown in annex 2 or an export certificate in the form shown in annex 3 to this Order.

(2) The provisions of paragraph (1) shall not apply to the importation and exportation of 1-phenyl-2-aminopropane (Psychedrine) or 1-phenyl-2-methylaminopropane (Pervitine), of their salts or of mixtures containing the said products or their salts.

6.(1) Import and export certificates shall be issued by the Minister of Health.

(2) An application for an import certificate shall contain the following particulars:

(i) the name and first name of the applicant or the name of the importing establishment, and the exact address;

(ii) the customs office in which customs clearance is to take place;

(iii) the country and place from which the consignment is to be sent;

(iv) the name and address of the exporter;

(v) the nature and quantity of narcotic drugs to be imported; furthermore, if the product to be imported is raw opium, the application shall state the country of origin of the opium, its quality and the percentage of its morphine content; if the product to be imported is any processed product or mixture containing narcotic drugs, the application shall state the net narcotic drug content;

(vi) a declaration that the narcotic drug is intended for medical, scientific or industrial purposes.

(3) An application for an export certificate shall contain the particulars mentioned in paragraph (2)(i) - (v), the provisions concerning the exporter applying mutatis mutandis to the importer. The application shall be accompanied by a certificate issued by the competent authority of the country of the importer, or a certificate issued by the competent Polish Consul, stating that the importing country does not issue such certificates and that the importer fulfils the conditions stipulated in the provisions in force in the country of destination concerning the importation of narcotic drugs.

7.(1) The transit of narcotic drugs through Polish territory shall only be permitted on the production of an export certificate issued by the competent service of the country of the exporter.

(2) A narcotic drug in transit through Polish territory may only be consigned to the country of destination specified in the export certificate, except where a further certificate is produced, issued by the authority which issued the original, showing a change in the country of destination.

(3) The provisions of paragraphs (1) and (2) shall not apply to 1-phenyl-2-aminopropane (Psychedrine) or to 1-phenyl-2-methylaminopropane (Pervitine), to their salts or to mixtures containing the said products or their salts.

8. Except in the case specified in section 10, customs officers shall order the return to the consignor of any consignment which fails to satisfy the conditions specified in sections 4 or 5.

9.(1) A consignment of narcotic drugs which is required to be returned to the consignor pursuant to section 8 may with the consent of the consignee be turned over free of charge to a social welfare establishment of the Health Service or sold to an undertaking authorized to obtain narcotic drugs.

(2) In any case in which narcotic drugs are to be turned over free of charge to a social welfare establishment of the Health Service, or sold to an undertaking, in the circumstances contemplated in paragraph 1, the consignee shall obtain the necessary authorisation from the undermentioned bodies, viz:

(i) If the consignment contains no more than 5 grammes of narcotic drugs in group IA or group II, from the provincial people's council within the competence of which the customs office is situated;

(ii) in all other cases, from the Minister of Health.

(3) The quantity of narcotic drugs referred to in paragraph (2)(i) shall be determined in mixtures and salts according to their net narcotic drug content.

(4) The authorization (paragraph (2)) shall state the nature and quantity of the narcotic drugs turned over or sold as aforesaid and the name of the social welfare establishment of the Health Service or of the undertaking receiving the product.

10. Customs officers shall provisionally seize and hold at the disposal of the prosecutor or court any consignment of narcotic drugs which contains:

(i) narcotic drugs in excess of or different in nature from those specified in the authorization.

(ii) narcotic drugs not mentioned in the certificate.

11. The importation, exportation and transit of narcotic drugs may be affected only through the customs offices specified in the certificate.

CHAPTER III

Manufacture and transformation of narcotic drugs

12. For the purposes of this Order, the manufacture of narcotic drugs means the production of narcotic drugs by synthesis (the appropriate chemical transformation of other substances) or the production of narcotic drugs in the form of alkaloids extracted from raw materials of plant origin.

13. For the purposes of this Order the transformation of narcotic drugs means:

(1) the production of derivatives of narcotic drugs which are raw materials of plant origin;

(2) the transformation of alkaloids which are narcotic drugs into their salts and the transformation of salts of such alkaloids into pure alkaloids;

(3) the production of mixtures of narcotic drugs and the preparation of narcotic drugs or mixtures thereof in a form used in therapy.

14.(1) The production and transformation of narcotic drugs may not be carried on except in industrial establishments which have duly obtained the authorization of the Minister of Health; the transformation of narcotic drugs may also be carried on in pharmacies under the direction of a pharmacist, a licensed druggist or a pharmaceutical assistant.

(2) The authorization shall specify the narcotic drugs which the establishment may manufacture or transform.

(3) The volume of annual production must be approved by the Minister of Health.

15. The authorization to produce and to transform narcotic drugs may be granted only to industrial establishments which will carry on the production or transformation in a manner and under conditions permitting the exercise of effective control.

16.(1) In every industrial establishment engaged in the manufacture or transformation of narcotic drugs, a licensed pharmacist must be made responsible for the manufacture, transformation, storage and placing on the market of the said drugs in accordance with the relevant statutory provisions.

(2) The duties of the said responsible pharmacist shall include:

(1) keeping control registers of narcotic drugs;

(2) supervising the storage of narcotic drugs;

(3) supervising the movement of narcotic drugs within the establishment and their placing on the market;

(4) ensuring that the narcotic drugs are used in accordance with the rules laid down by the establishment.

17.(1) Industrial establishments in which narcotic drugs are manufactured or transformed must keep a control register of narcotic drugs for the production division, in accordance with the model shown in annex 4, and a control register for the stores showing receipts and issues in accordance with the model shown in annex 5 hereto.

(2) The control register, which shall consist of numbered sheets, shall be checked and initialled by the praesidium of the people's council.

(3) Entries in respect of each kind of narcotic drug shall be made on a separate page of the control register (account sheet) on the date on which the operation is effected.

(4) The name and address of suppliers of poppy straw may be omitted from the control register relating to incoming and outgoing supplies.

(5) Industrial establishments which are engaged only in the transformation of narcotic drugs shall not enter in the control registers the data referred to in paragraph (1)which relate to narcotic drugs in group 2.

(6) All documents relating to the manufacture, transformation and placing on the market of narcotic drugs and the registers for the control of the movement of such drugs shall be kept on the premises of the industrial establishment engaged in the particular activity for three years from the end of the calendar year during which the last operation was carried out, unless they must be preserved for a longer period in pursuance of other provisions.

(7) On the winding up of an industrial establishment before the expiry of the period referred to in paragraph (6)the documents and registers shall be delivered to the praesidium of the provincial people's council in whose district the establishment is situated.

18.(1) Industrial establishments authorized to manufacture or transform narcotic drugs shall be required to file quarterly reports, prepared in accordance with the prescribed model.

(2) The reports referred to in paragraph (1)shall be submitted to the Ministry of Health during the month following the period to which the particular report relates.

19.(1) Industrial establishments which manufacture and transform narcotic drugs may not release the said drugs except on production of a written order showing the commercial name and the address of the purchaser, the quantity and kind of drugs purchased, their destination, the signature of the purchaser, the date of the order and the number of the licence issued for the purchase of narcotic drugs.

(2) Where the firm or person placing the order is not known to the producing or transforming establishment, the latter must before delivering the narcotic drug require the licence for the purchase of the said narcotic drugs to be produced.

(3) Only persons duly authorized in writing may accept delivery of narcotic drugs consigned to an establishment or undertaking. The receipt for the delivery shall state the kinds and quantities of drugs delivered and the date of delivery and shall be signed by the authorized person.

(4) Where narcotic drugs are shipped by post or by rail the shipping document shall serve as a receipt.

CHAPTER IV

Wholesale trade in narcotic drugs

20.(1) Wholesale trade in narcotic drugs may be conducted only by wholesale pharmaceutical and chemical establishments which have duly obtained authorization for that purpose.

(2) Permits for the wholesale trade in specified kinds of narcotic drugs shall be issued by the Minister of Health; the period of validity of any such permit shall be one year.

(3) The provisions of sections 15, 16 and 19 shall apply mutatis mutandis to undertakings engaged in the wholesale trade in narcotic drugs.

21.(1) Undertakings engaged in the wholesale trade in narcotic drugs shall not deliver such drugs except to:

(1) undertakings authorized to manufacture or transform narcotic drugs;

(2) undertakings authorized to engage in the wholesale trade in narcotic drugs;

(3) pharmacies under the direction of a pharmacist, licensed druggist, or pharmaceutical assistant, first aid stations and public veterinary establishments;

(4) institutions of higher education, scientific institutes and other scientific establishments and secondary schools which possess the required permits.

(2) Orders from first-aid stations and public veterinary establishments must be signed by the medical practitioner (veterinary surgeon) responsible for the handling of narcotic drugs in the establishment in question and orders from pharmacies must be signed by the director of the pharmacy.

22.(1) Undertakings engaged in the wholesale trade in narcotic drugs shall be required to keep control registers of the inward and outward movements of narcotic drugs in accordance with the model shown in annex 5 hereto.

(2) The provisions of section 17, paragraphs (2), (3), (5), (6) and (7), shall be applicable mutatis mutandis.

23.(1) All wholesale undertakings shall submit an annual report to the Ministry of Health on the movement of narcotic drugs, prepared in accordance with the presented model.

(2) The report referred to in paragraph (1) must be submitted to the Ministry of Health during the month following the period covered by the report.

CHAPTER V

Retail trade

24. Pharmacies under the direction of a pharmacist, a licensed druggist or a pharmaceutical assistant, shall be authorized to engage in the retail trade in narcotic drugs in groups I A, I B and II.

25.(1) Pharmacies may not deliver narcotic drugs except in a form intended for medical use and on the prescription of a medical practitioner, a dentist, a medical assistant or a veterinary surgeon, or except on the order of a public health welfare establishment or a public veterinary establishment possessing the required permit.

(2) The prescription of narcotic drugs by medical practitioners, dentists and medical assistants shall be governed by separate regulations.

(3) Prescriptions by veterinary surgeons may relate only to narcotic drugs which are to be administered to and used in the treatment of animals, and such prescriptions shall state the name, first name, professional title and address of the prescribing veterinary surgeon, the kind and quantity of the narcotic drug, the method of use, the species of the animal to be treated, and the name and address of the owner of the animal or the notation "for use in my own practice". The quantity of narcotic drugs contained in a prescription made out by a veterinary surgeon may not exceed five times the single dose prescribed and, in the case of prescriptions bearing the notation "for use in my own practice", the quantity shall not exceed twenty times the maximum single dose for human beings.

26.(1) Pharmacies shall be authorized to sell 20 grammes of Guttae Inoziemcovi without prescription.

(2) Pharmacies may issue without a prescription 2.5 grammes of tinctura opii simplex for first-aid purposes. In such a case the identity of the person receiving the drug shall be verified and his name, first name and address shall be entered in the narcotic drugs control register.

27.(1) Pharmacies shall keep, as evidence of the outward movement of narcotic drugs, the prescriptions on production of which they dispensed such drugs and shall deliver a copy of the prescription to the purchaser.

(2) It shall be unlawful to dispense narcotic drugs against a copy of a prescription.

28. If a pharmacy has any doubt regarding the authenticity of an order or a prescription calling for narcotic drugs or regarding the competence of the establishment or person in question to acquire the said drugs, it shall apply to the praesidium of the provincial people's council for guidance in the matter.

29.(1) Pharmacies shall be required to keep a control register of the movement of narcotic drugs in groups I A and I B in conformity with the model shown in annex 6 hereto.

(2) The provisions of section 17, paragraphs (6) and (7), shall be applicable mutatis mutandis.

CHAPTER VI

Manufacture and use of narcotic drugs for scientific and educational purposes

30.(1) Institutions of higher education, scientific institutes and other scientific establishments and their local branches may possess, manufacture and use narcotic drugs for scientific purposes, including narcotic drugs in groups I A, I B and I C, provided that they are duly authorized by the praesidium of the provincial people's council in whose district the seat of the institution, institute or establishment in question, or its local branch, is situated.

(2) The provisions of paragraph (1) shall apply mutatis mutandis to secondary schools, subject to the proviso that the said schools may not possess or use narcotic drugs in group I C.

(3) The authorization shall state the kind and quantity of the narcotic drug and the purpose for which it is intended.

(4) The directors of the establishments referred to in paragraphs (1) and (2) shall be responsible for the proper storage and use of narcotic drugs.

(5) The provisions of section 15, section 17 paragraphs (2), (3), (6) and (7), and section 19, paragraph (3), shall apply mutatis mutandis to the establishments referred to in paragraphs (1) and (2). The said establishments shall be required to submit an annual report, prepared in conformity with the prescribed model, to the praesidium of the provincial people's council and to keep a control register in conformity with the model shown in annexes 7 and 8 hereto.

31. The application for the authorization referred to in section 30 shall be submitted:

(1) in the case of institutions of higher education, by the rector;

(2) in the case of scientific institutes and other scientific establishments, by the director;

(3) in the case of secondary schools, by the superintendent (or equivalent authority).

CHAPTER VII

Purchase and use of narcotic drugs by social welfare establishments of the Health Service and public veterinary establishments

32. The provisions of chapter V shall apply to the purchase, storage and delivery of narcotic drugs in social welfare establishments of the Health Service which have a dispensary under the direction of a licensed pharmacist, an authorized dispensary manager, or an authorized druggist.

33.(1) Social welfare establishments of the Health Service and public veterinary establishments in which there is no dispensary may not buy narcotic drugs unless they are under the direction of a medical practitioner or a veterinary surgeon and are duly authorized to buy such drugs by the praesidium of the provincial people's council.

(2) The authorization referred to in paragraph (1) shall specify the narcotic drugs which the establishment may possess.

(3) No authorization shall be required for the purchase of narcotic drugs in group II.

(4) Stocks of narcotic drugs other than narcotic drugs in group II may not exceed the quantity consumed in one month and, in first aid stations, the quantity consumed in three months.

34. The handling of narcotic drugs in conformity with the statutory regulations in the establishments referred to in section 33 shall be the responsibility of the medical practitioner or veterinary surgeon thereunto duly authorized by the director of the establishment. The person vested with such responsibility shall have exclusive authority to issue narcotic drugs.

35.(1) Rural dispensaries conducted by medical assistants or nurses may possess stocks of narcotic drugs of the description and in the quantities specified below:

Codeinum phosphoricum 0.02 - 50 tablets
Guttae Inoziemcovi - 50 grammes

(2) Maternity centres may keep the following stocks of narcotic drugs:

Tinctura Opii Simplex - 2 grammes
Extr. opii - 2 suppositories
Pantopon 0.02 - 2 ampoules

(3) The establishments referred to in paragraphs (1) and (2) may not purchase narcotic drugs except on production of an order signed by the medical practitioner responsible for the supervision of the said establishment.

36.(1) Social welfare establishments of the Health Service shall be required to keep control registers for narcotic drugs in groups I A and I B in conformity with the model shown in annex 9 and public veterinary establishments shall keep control registers in conformity with the model shown in annex 10 hereto.

(2) First aid stations shall be required to make the corresponding entries in the control register before the expiry of forty-eight hours.

(3) The provisions of section 17, paragraphs (6) and (7), shall be applicable mutatis mutandis.

CHAPTER VIII

Use of narcotic drugs by industrial establishments

37.(1) Industrial establishments which use narcotic drugs in their production or for purposes of analysis and which do not produce such drugs may apply to the praesidium of the provincial people's council for authorization to buy and use the said drugs.

(2) The authorization referred to in paragraph (1) shall state the name and address of the establishment, the kind, quantity and intended use of the narcotic drugs and the period of validity of the authorization.

(3) The authorization referred to in paragraph (1) may be valid for a single purchase or for the purchase of a specified quantity of narcotic drugs during the course of a calendar year.

(4) The authorization shall be returned on its expiry to the praesidium of the provincial people's council which issued it.

(5) The establishment in question shall keep the authorizations issued to it in such a way as to prevent their being used for illicit purposes.

(6) The provisions of section 17 shall be applicable mutatis mutandis.

CHAPTER IX

The storing of narcotic drugs

38. Establishments, undertakings and persons possessing an authorization for the manufacture, transformation, sale or use of narcotic drugs may possess only the quantities and kinds of drugs indicated in the authorization.

39. Medical practitioners, dentists and veterinary surgeons may possess only the kinds and quantities of narcotic drugs which they require in the exercise of their profession.

40. Sick persons and the owners of sick animals may possess only the quantities of narcotic drugs prescribed by the medical practitioner or veterinary surgeon.

41.(1) Possessors of narcotic drugs shall ensure that the said drugs are not used for illicit purposes.

(2) In establishments and undertakings narcotic drugs shall be kept under lock in suitably protected separate cabinets.

(3) Factories manufacturing pharmaceutical products and wholesale establishments shall, in addition, place the cabinets containing narcotic drugs in suitably equipped stores, provided with doors made of iron or covered with sheet iron, and windows protected by grilles. Cocaine shall be kept in iron cabinets or safes.

(4) The provisions of paragraphs (2) and (3) shall not apply to narcotic drugs in group II.

CHAPTER X

Transitional and final provisions

42. Authorizations issued in pursuance of the provisions in force before the date of this Order for the manufacture, transformation, placing on the market, use, or possession of narcotic drugs shall cease to be valid on 31 December 1956.

43. Establishments and undertakings shall, as from 1 January 1957, keep narcotic drugs control registers in conformity with the rules and models laid down in this Order.

44. If any person, establishment or undertaking now in possession of narcotic drugs does not obtain the authorizations provided for in this Order, then the person, establishment or undertaking in question shall be required to deliver the said drugs to authorized establishments not later than 31 December 1956.

45. Possessors of narcotic drugs in group I C shall report their stocks of the drugs in question to the Ministry of Health not later than 31 October 1956.

46. The provisions concerning the praesidiums of provincial people's councils shall apply mutatis mutandis to the praesidiums of the people's councils of the towns of Warsaw and Lodz.

47.(1) The provisions of this Order, with the exception of the provisions of chapter II, shall not apply to Health Service establishments under the Ministers of National Defence and the Interior.

(2) The establishments referred to in paragraph (1) shall, however, conform with the provisions of the Order in purchasing narcotic drugs from a factory manufacturing or a wholesale establishment dealing in pharmaceutical products to which this Order applies.

(3) The Health Service agencies under the ministries referred to in paragraph (1) shall communicate to factories manufacturing and wholesale establishments dealing in pharmaceutical products a list of the establishments which are authorized to purchase narcotic drugs.

48. The undermenticned provisions, which have hitherto governed the matters regulated by this Order, shall cease to have effect:

(1) Order of the Minister of the Interior and the Minister of Justice of 15 December 1931, to extend to codeine the application of the regulations governing import and export certificates (Dz.U. 1932, No. 12, item 72).

(2) Order of the Minister of the Interior and the Minister of Justice of 1 March 1928, concerning narcotic substances and products (Dz.U. No. 52, item 490).

(3) Order of the Minister of the Interior of 20 May 1929 concerning the retail sale of narcotic drugs and products (Dz.U. No. 48, item 402).

(4) Order of the Minister of the Interior of 15 March 1930 classifying certain narcotic drugs and products as dangerous substances. (Dz.U. No. 36, item 404).

(5) Order of the Minister of Social Welfare of 19 June 1937 classifying certain narcotic drugs and products as dangerous substances. (Dz.U. 1937 No. 49, item 379; 1948, No. 9, item 63 and 1950, No. 25, item 230).

(6) The provisions of section 23 (a) I, Section 24 III, paragraph 5, and section 25, paragraph 5(a) of the Order of the Minister of Finance of 9 October 1934. Regulations to give effect to the Customs Code (Dz.U. No. 90, item 820 and subsequent amendments).

49. This Order shall enter into effect on the date of its publication.

J. Sztachelski, Minister of Health

K. Dabrowski, Minister of Foreign Trade

Annexes to the Order of the Ministers of Health
and Foreign Trade of 13 September 1956 (No. 196)

Annex 1

Narcotic Drugs in Group I A

(1) Raw opium
(2) Medicinal opium and mixtures containing medicinal opium
(3) Prepared opium and mixtures containing prepared opium
(4) Morphine
(5) Cocaine
(6) Dihydrocodeinone /Hydrocodone/[2] and its tartrate, Dicodide
(7) Dihydrohydroxycodeinone /Oxycodone/ and its hydrochloride, Eucodal
(8) 1-methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester (Dolantine, Pethidine)
(9) 1-phenyl-2-aminopropane (Psychedrine)
(10) Salts of the products enumerated in Nos. (3)-(9) and mixtures containing the said products or their salts.

Narcotic Drugs in Group I B

(1) Coca leaf (Folium coca)
(2) [illegible] cannabis indicae)
(3) [illegible] of the products listed under (1) and (2)
(4) Esters of morphine, with the exception of heroin
(5) Ethers of morphine, with the exception of methylmorphine /Codeine/ and ethylmorphine.
(6) Morphine-N-oxyide (Genomorphine)
(7) Other pentavalent nitrogen morphine derivatives
(8) Dihydromorphine and its hydrochloride, Paramorfan
(9) Dihydromorphinone /Hydromorphone/ and its hydrochloride, Dilaudid
(10) Tropacocaine
(11) Ecgonine
(12) Benzoylecgonine
(13) Methylecgonine
(14) Acetyldihydrocodeinone /Thebacon/ and its hydrochloride, Acedicone.
(15) Dihydrodesoxymorphine /Desomorphine/
(16) Methyldihydromorphine
(17) Thebaine
(18) 4,4-diphenyl-6-piperidino-3-hexanone (Hexalgon)
(19) 1-methyl-4-(3-hydroxyphenyl)-piperidine-4-carboxylic acid ethyl ester (Bemidone) /Hydroxypethidine/
(20) α -1,3-dimethyl-4-phenyl-4-propionoxypiperidine (Alphaprodine)
(21) β -1,3-dimethyl-4-phenyl-4-propionoxypiperidine (Betaprodine)
(22) 6-dimethylamino-4,4-diphenyl-5-methyl-3-hexanone (Isomethadone)
(23) 6-dimethylamino-4,4-diphenyl-3-heptanol (Methadone)3/
(24) α -6-dimethylamino-4,4-diphenyl-3-heptanol /Alphamethadol/
(25) 6-dimethylamino-4,4-diphenyl-3-acetoxyheptane (Acetylmethadol)
(26) α -6-dimethylamino-4,4-diphenyl-3-acetoxyheptane (Alphacetylmethadol)
(27) β -6-dimethylamino-4,4-diphenyl-3-acetoxyheptane (Betacetylmethadol)
(28) β -1-methyl-3-ethyl-4-phenyl-4-propionoxypiperidine (Meprodine) /Betameprodine/
(29) DL-3-hydroxy-N-methylmorphinan (Racemorphan)
(30) L-3-hydroxy-N-methylmorphinan (Levorphanol)
(31) DL-3-methoxy-N-methylmorphinan (Racemethorphan)
(32) L-3-methoxy-N-methylmorphinan (Levomethorphan)
(33) 3-dimethylamino-1,1-di-(2'-thienyl)-1-butene /Dimethylthiambutene/
(34) 3-ethylmethylamino-1,1-di-(2'-thienyl)-1-butene /Ethylmethylthiambutene/
(35) 4,4-diphenyl-6-dimethylamino-heptanone-3 (Methadone, Mecodine)
(36) 1-phenyl-2-methylaminopropane (Pervitine)
(37) Salts of the products enumerated in Nos. (4) to (36) and mixtures containing the said products or their salts.

3/ Note by the Secretariat: The formula given is that of Dimepheptanol.

Annex 1 (contd.)

Narcotic Drugs in Group I C

(1) Opium for smoking
(2) Hashish
(3) Diacetylmorphine (heroin)
(4) 4-(3-hydroxyphenyl)-1-methyl-4-piperidyl ethyl ketone (Ketobemidone)
(5) Salts of the products enumerated in Nos. (3) and (4) and mixtures containing the said products or their salts.

Narcotic Drugs in Group II

(1) Methylmorphine (Codeine)
(2) Ethylmorphine and its hydrochloride (Dionine)
(3) Dihydrocodeine and its tartrate, Paracodine
(4) Acetyldihydrocodeine
(5) Salts of the products enumerated in Nos. (1)-(4) and mixtures containing the said products or their salts.

Annex 2

IMPORT CERTIFICATE

The Ministry of Health, being responsible in the territory of the People's Republic of Poland for the control of narcotic drugs in conformity with the International Opium Convention signed at Geneva on 19 February 1925 (Dz.U. 1927 No. 108, item 120), the Convention for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs, signed at Geneva on 13 July 1931, (Dz.U. 1934, No. 12, item 97), and the Protocol, signed in Paris on 19 November 1948, bringing under international control drugs outside the scope of the aforesaid Convention of 13 July 1931 (as amended by the Protocol signed at Lake Success on 11 December 1946) (Dz.U. 1952, No. 9, item 48), hereby authorizes the following importation

(a) . . . . . .

(name and address of importer)

(b) . . . . . .

(description and quantity of narcotic drug)

(c) . . . . . .

(name and address of exporter)

Purposes for which the said drugs are intended:

The drugs in question may be imported not later than (date):

through the Customs office at:

Warsaw, date:

. . . . . .

(signature)

Annex 3

EXPORT CERTIFICATE

The Ministry of Health, being responsible in the territory of the People's Republic of Poland for the control of narcotic drugs in conformity with the International Opium Convention signed at Geneva on 19 February 1925 (Dz.U. 1927 No. 108, item 120), the Convention for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs, signed at Geneva on 13 July 1931, (Dz.U. 1934, No. 12, item 97) and the Protocol, signed in Paris on 19 November 1948, bringing under international control drugs outside the scope of the aforesaid Convention of 13 July 1931 (as amended by the Protocol signed at Lake Success on 11 December 1946) (Dz.U. 1952, No. 9, item 48), authorizes the following exportation:

(a) . . . . . .

(name and address of importer)

(b) . . . . . .

(description and quantity of narcotic drug)

(c) . . . . . .

(name and address of exporter)

Purposes for which the above-mentioned drugs are intended:

The drugs in question may be exported not later than (date):

Through the Customs office at:

Import certificate No. :

issued by:

Warsaw, date: . . . . . .

(signature)

Annex 4

NARCOTIC DRUGS CONTROL REGISTER

kept by: . . . . . .
(name and address of industrial undertaking)

Semi-finished product sheet: . . . . . .
(description

Entry number	Date manufactured or received	Substance from which product is made (kind and quantity of raw material, narcotic drug content)	Quantity manufactured or received	Net narcotic drug content	Issue number	Date manufacture was begun	Quantity used	Used for the manufacture of what narcotic drug	Date on which semi-finished product was released	To whom released (name and address of firm)	Quantity released	Observations
1	2	3	4	5	6	7	8	9	10	11	12	13

Annex 4 (contd.)

Finished product sheet: . . . . . .
(description)

Entry number	Date of manufacture	Substance from which manufactured (designation of semi-finished product)	Issue number on the semi-finished product sheet	Quantity of semi-finished product	Narcotic drug content in the semi-finished products	Quantity of finished product manufactured	Date released to store	Quantity released to store	Quantity removed for analysis	Shortage	Observations
1	2	3	4	5	6	7	8	9	10	11	12

Annex 5

REGISTER FOR THE CONTROL OF INCOMING AND OUTGOING MOVEMENT OF NARCOTIC DRUGS

. . . . . .
(name and address of firm)

. . . . . .
(description of product)

Entry number	Incoming			Outgoing					Balance	Observations
	Date on which product was obtained	Quantity	Obtained from: (address of supplier)	Issue number	Date of sale	Quantity	Buyer (address)	Purpose for which acquired		
1	2	3	4	5	6	7	8	9	10	11

Annex 6

NARCOTIC DRUGS CONTROL REGISTER

of pharmacy . . . . . .
(name and address)

sheet: . . . . . .
(description of narcotic drug, form, dose)

Entry number	Entry			Issue						Balance	Observations
	Date on which product was obtained	Obtained from: (name of firm, invoice number)	Quantity obtained	Issue number	Delivery date	Delivered on the basis of (name of medical practitioner)	Serial number of document	Name and first name of patient or owner of animal	Quantity delivered		
1	2	3	4	5	6	7	8	9	10	11	12

Annex 7

NARCOTIC DRUGS CONTROL REGISTER

. . . . . .
(name and address of establishment)

. . . . . .
(description of narcotic drug, form, dose)

Entry number	Entry			Issue				Observations
	Designation and quantity of raw material or source of supply of narcotic drug (name of firm and invoice number)	Date on which drug was manufactured or obtained	Quantity obtained or manufactured	Issue number	Date used	Quantity used	Purpose for which used. Name and address of buyer	
1	2	3	4	5	6	7	8	9

For establishments using purchased narcotic drugs

Annex 8

NARCOTIC DRUGS CONTROL REGISTER

. . . . . .
(name and address of scientific establishment)

. . . . . .
(description of narcotic drug, form, dose)

Entry number	Entry			Issue				Observations
	Date product was obtained	Quantity	Obtained from: (name of firm and invoice number)	Issue number	Date used	Quantity used	Purpose for which used	
1	2	3	4	5	6	7	8	9

Annex 9

NARCOTIC DRUGS CONTROL REGISTER

. . . . . .
(name and address of establishment)

sheet: . . . . . .
(description of narcotic drug, form, dose)

Entry number	Entry				Issue				Observations
	Date product was obtained	Quantity obtained	Obtained from: (name and address of supplying firm, number and date of invoice)	Issue number	Date used	Quantity used	Name and address of patient	Prescribed by (name of medical practitioner)	
1	2	3	4	5	6	7	8	9	10

Annex 10

NARCOTIC DRUGS CONTROL REGISTER

. . . . . .
(name and address of establishment)

sheet: . . . . . .
(description of narcotic drug, form, dose)

Entry number	Entry			Issue						Observations
	Date product was obtained	Quantity obtained	Obtained from: (name and address of supplier, number and date of invoice)	Issue number	Date used	Quantity used	Name and address of owner of animal undergoing treatment	Species of animal	Prescribed by (name of veterinary surgeon)	
1	2	3	4	5	6	7	8	9	10	11